[go: up one dir, main page]

MXPA04001963A - Diagnostico de carcinomas. - Google Patents

Diagnostico de carcinomas.

Info

Publication number
MXPA04001963A
MXPA04001963A MXPA04001963A MXPA04001963A MXPA04001963A MX PA04001963 A MXPA04001963 A MX PA04001963A MX PA04001963 A MXPA04001963 A MX PA04001963A MX PA04001963 A MXPA04001963 A MX PA04001963A MX PA04001963 A MXPA04001963 A MX PA04001963A
Authority
MX
Mexico
Prior art keywords
he4a
soluble
subject
cell surface
provides
Prior art date
Application number
MXPA04001963A
Other languages
English (en)
Inventor
A Ledbetten Jeffrey
Original Assignee
Pacific Northwest Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pacific Northwest Res Inst filed Critical Pacific Northwest Res Inst
Publication of MXPA04001963A publication Critical patent/MXPA04001963A/es

Links

Classifications

    • G01N33/57545—
    • G01N33/575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • G01N33/57585—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

La invencion esta dirigida a composiciones y metodos para la deteccion de una condicion maligna, y se refiere al descubrimiento de las formas soluble y de superficie celular de polipeptidos de HE4a, incluyendo HE4a que es sobreexpresado en carcinomas ovaricos; en particular, la invencion provee una secuencia de acido nucleico que codifica para HE4a, y provee tambien un metodo para seleccionar la presencia de una condicion maligna en un sujeto, detectando reactividad de un anticuerpo especifico de un polipeptido de HE4a con una molecula de ocurrencia natural en forma soluble y/o de superficie celular en una muestra de dicho sujeto, y mediante seleccion por hibridacion usando una secuencia de nucleotidos de HE4a, asi como otras ventajas relacionadas.
MXPA04001963A 2001-08-29 2002-08-29 Diagnostico de carcinomas. MXPA04001963A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31653701P 2001-08-29 2001-08-29
PCT/EP2002/009653 WO2003021273A2 (en) 2001-08-29 2002-08-29 Diagnosis of carcinomas

Publications (1)

Publication Number Publication Date
MXPA04001963A true MXPA04001963A (es) 2005-02-17

Family

ID=23229467

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001963A MXPA04001963A (es) 2001-08-29 2002-08-29 Diagnostico de carcinomas.

Country Status (11)

Country Link
US (4) US7270960B2 (es)
EP (3) EP2913673B1 (es)
JP (5) JP2005501549A (es)
KR (1) KR20040062534A (es)
CN (1) CN1813188A (es)
BR (1) BR0212211A (es)
CA (1) CA2459077C (es)
ES (1) ES2628952T3 (es)
MX (1) MXPA04001963A (es)
RU (1) RU2004109149A (es)
WO (1) WO2003021273A2 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087250A1 (en) * 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
US7270960B2 (en) * 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
US7601505B2 (en) * 2003-05-29 2009-10-13 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
ES2622522T3 (es) 2003-08-26 2017-07-06 The Regents Of The University Of Colorado, A Body Corporate Inhibidores de la actividad proteasa de serina y su uso en métodos y composiciones para el tratamiento de infecciones bacterianas
EP2051077A3 (en) * 2003-10-07 2009-05-27 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
WO2005072341A2 (en) * 2004-01-21 2005-08-11 Fujirebio America, Inc. Detection of mesothelin-/megakaryocyte potentiating factor-related peptides in peritoneal fluid for assessment of the peritoneum and the peritoneal cavity
EP1716168A4 (en) * 2004-01-21 2009-06-24 Fujirebio America Inc DETECTION OF PEPTIDES RELATED TO THE URINARY MESOTHELIN / MEGAKARYOCYTE POTENTIATING FACTOR FOR THE STUDY OF MESOTHELIOMES
CA2578613A1 (en) * 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
US20090075305A1 (en) * 2005-05-02 2009-03-19 The Brigham And Womern's Hospital, Inc. Diagnostic serum antibody profiling
CN105823877B (zh) * 2005-06-22 2022-02-25 约翰·霍普金斯大学 卵巢癌的生物标记：ctap3-相关蛋白质
JP5164855B2 (ja) 2006-01-04 2013-03-21 フジレビオ アメリカ、インク． 子宮内膜または子宮癌を評価するためのｈｅ４及びそのほかの生化学的マーカーの使用
EP1987360B1 (en) * 2006-01-27 2012-03-07 Tripath Imaging, Inc. Methods for identifying patients with an increased likelihood of having ovarian cancer and compositions therefor
RU2328735C2 (ru) * 2006-08-16 2008-07-10 Федеральное государственное учреждение "Российский научно-исследовательский институт травматологии и ортопедии им. Р.Р. Вредена Федерального агентства по высокотехнологичной медицинской помощи" (ФГУ "РНИИТО им. Р.Р. Вредена Росмедтехнологий") Способ тестирования трупов-доноров на пригодность их тканей к трансплантации
US7811778B2 (en) 2006-09-06 2010-10-12 Vanderbilt University Methods of screening for gastrointestinal cancer
EP2121761A1 (en) * 2007-03-09 2009-11-25 Tripath Imaging, Inc. He4 monoclonal antibodies and methods for their use
WO2008121391A2 (en) 2007-03-29 2008-10-09 Fujirebio Diagnostics, Inc. Use of he4 for assessment of breast cancers
WO2009099561A2 (en) * 2008-01-31 2009-08-13 The Brigham And Womens' Hospital, Inc. Urinary ca125 peptides as biomarkers of ovarian cancer
US8476026B2 (en) * 2008-04-01 2013-07-02 The Brigham And Women's Hospital, Inc. Biomarkers of ovarian cancer
US8993347B2 (en) * 2009-12-17 2015-03-31 Cornell University Methods for detecting antibodies in mucosal samples and device for sampling mucosal material
US20130095503A1 (en) * 2010-01-05 2013-04-18 University Of Cincinnati Serum spla2-iia as diagnosis marker for prostate and lung cancer
BR112013004458A2 (pt) * 2010-08-26 2016-06-07 Univ Washington Ct Commerciali método e kit para detectar a presença de células que expressam he-4 em um indivíduo humano, e, método para o monitoramento de eficácia de tratamento de um paciente de câncer humano
CA2827618C (en) * 2011-02-17 2019-08-06 Fujirebio Diagnostics, Inc. Compositions and methods of use for the determination of he4a
WO2012115820A2 (en) * 2011-02-24 2012-08-30 Vermillion, Inc. Biomarker panels, diagnostic methods and test kits for ovarian cancer
US9980982B2 (en) 2011-06-06 2018-05-29 Women & Infants Hospital Of Rhode Island HE4 based therapy for malignant disease
CA2839917A1 (en) 2011-06-24 2012-12-27 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for alpha-1 antitrypsin fusion molecules
KR20220003656A (ko) 2011-06-28 2022-01-10 인히브릭스, 인크. 세르핀 융합 폴리펩타이드 및 이의 이용 방법
CN103946388A (zh) * 2011-06-28 2014-07-23 英伊布里克斯有限责任公司 Wap结构域融合多肽及其使用方法
US10400029B2 (en) 2011-06-28 2019-09-03 Inhibrx, Lp Serpin fusion polypeptides and methods of use thereof
PT2731972T (pt) 2011-07-15 2018-03-09 Eisai R&D Man Co Ltd Anticorpos anti-recetor alfa de folatos (frα) e utilizações dos mesmos
KR20140137347A (ko) 2012-01-10 2014-12-02 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 알파-1 안티트립신 융합 분자용 조성물, 방법 및 용도
CN103575902B (zh) * 2012-08-03 2015-07-29 河南生生医疗器械有限公司 一种时间分辨荧光法四项综合检测卵巢癌试剂盒及其应用
US9903871B2 (en) * 2014-07-15 2018-02-27 Temple University Of The Commonwealth System Of Higher Education Stabilized peptide fragments from nucleoredoxin X1 and uses thereof
NZ740855A (en) * 2015-08-21 2022-04-29 Crage Medical Co Ltd Fully human anti-mesothelin antibodies and immune effector cells targeting mesothelin
RU2641094C1 (ru) * 2016-12-22 2018-01-15 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Способ ранней диагностики серозной карциномы яичника высокой степени злокачественности на основании изменения клеточного состава эпителия маточной трубы
WO2019060716A1 (en) 2017-09-25 2019-03-28 Freenome Holdings, Inc. SAMPLE EXTRACTION METHODS AND SYSTEMS
WO2020018381A1 (en) * 2018-07-18 2020-01-23 The Regents Of The University Of California Kidney injury treatment
JP7539369B2 (ja) * 2019-04-02 2024-08-23 大塚製薬株式会社 病態情報生成方法、病態情報生成システム、ｈｅ４糖鎖分析キット及びｈｅ４
KR20220015367A (ko) 2019-05-31 2022-02-08 프리놈 홀딩스, 인크. 메틸화된 핵산의 고심도 시퀀싱 방법 및 시스템
KR20230017169A (ko) 2020-03-31 2023-02-03 프리놈 홀딩스, 인크. 핵산 메틸화 분석을 통한 결장직장암 검출을 위한 방법 및 시스템
EP4169941A4 (en) * 2020-06-23 2024-06-12 Mitsui Chemicals, Inc. METHODS FOR DETECTION OF ADENOCARCINOMAS AND EXAMINATION KIT
EP4226153A4 (en) 2020-10-05 2025-03-19 Freenome Holdings, Inc. Markers for the early detection of colon cell proliferative disorders
WO2022140116A1 (en) 2020-12-21 2022-06-30 Freenome Holdings, Inc. Markers for the early detection of colon cell proliferative disorders
CN117940567A (zh) * 2021-09-16 2024-04-26 克迈恩有限公司 调控wfdc2的表达的反义化合物
US20240376473A1 (en) * 2021-09-16 2024-11-14 Qmine Co., Ltd. Antisense compound for modulating wfdc2 expression

Family Cites Families (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4713352A (en) 1981-08-31 1987-12-15 Sloan-Kettering Institute For Cancer Reseach Monoclonal antibody panel for early diagnosis and therapy of renal carcinoma
US4612282A (en) 1981-12-15 1986-09-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Monoclonal antibodies reactive with human breast cancer
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
SE8300693L (sv) 1983-02-09 1984-08-10 Sven Lofdahl Sett att framstella och isolera proteiner och polypeptider samt en hybridvektor for detta
US4579827A (en) 1983-03-11 1986-04-01 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to human gastrointestinal cancers and hybridoma method of production of the monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5190931A (en) 1983-10-20 1993-03-02 The Research Foundation Of State University Of New York Regulation of gene expression by employing translational inhibition of MRNA utilizing interfering complementary MRNA
US4753894A (en) 1984-02-08 1988-06-28 Cetus Corporation Monoclonal anti-human breast cancer antibodies
US5272254A (en) 1984-10-02 1993-12-21 Biogen Inc. Production of streptavidin-like polypeptides
EP0198015B2 (en) 1984-10-02 1995-07-19 Biogen, Inc. Production of streptavidin-like polypeptides
ZA858371B (en) 1984-11-02 1987-03-25 Oncogen Monoclonal antibodies for human non-small cell lung carcinomas
US5391485A (en) 1985-08-06 1995-02-21 Immunex Corporation DNAs encoding analog GM-CSF molecules displaying resistance to proteases which cleave at adjacent dibasic residues
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
DE3853515T3 (de) 1987-05-21 2005-08-25 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung.
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
GB8723661D0 (en) 1987-10-08 1987-11-11 British Bio Technology Synthetic gene
US5093245A (en) 1988-01-26 1992-03-03 Applied Biosystems Labeling by simultaneous ligation and restriction
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5087617A (en) 1989-02-15 1992-02-11 Board Of Regents, The University Of Texas System Methods and compositions for treatment of cancer using oligonucleotides
US5168053A (en) 1989-03-24 1992-12-01 Yale University Cleavage of targeted RNA by RNAase P
US5144019A (en) 1989-06-21 1992-09-01 City Of Hope Ribozyme cleavage of HIV-I RNA
US5272262A (en) 1989-06-21 1993-12-21 City Of Hope Method for the production of catalytic RNA in bacteria
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
DE4002981C2 (de) 1990-02-01 1998-03-12 Ihf Inst Fuer Hormon Und Fortp Humane, Epididymis-spezifische Polypeptide und deren Verwendung zur Therapie und Diagnose männlicher Infertilität
US5180818A (en) 1990-03-21 1993-01-19 The University Of Colorado Foundation, Inc. Site specific cleavage of single-stranded dna
US5135917A (en) 1990-07-12 1992-08-04 Nova Pharmaceutical Corporation Interleukin receptor expression inhibiting antisense oligonucleotides
US6072039A (en) 1991-04-19 2000-06-06 Rohm And Haas Company Hybrid polypeptide comparing a biotinylated avidin binding polypeptide fused to a polypeptide of interest
DE4135543A1 (de) 1991-10-28 1993-04-29 Boehringer Mannheim Gmbh Rekombinantes core-streptavidin
CA2131003A1 (en) * 1992-05-26 1993-12-09 Raymond G. Goodwin Novel cytokine that binds cd30
EP0644938A1 (en) 1992-05-29 1995-03-29 E.I. Du Pont De Nemours And Company PRODUCTION OF STREPTAVIDIN FROM $i(BACILLUS SUBTILIS)
US5935824A (en) * 1996-01-31 1999-08-10 Technologene, Inc. Protein expression system
US6313269B1 (en) 1997-03-14 2001-11-06 Smithkline Beecham Corporation Tumor necrosis factor related receptor, TR6
WO1999023218A1 (fr) 1997-11-05 1999-05-14 Sumitomo Electric Industries, Ltd. PROTEINES DE FIXATION DE p16, GENE DE CES PROTEINES ET ANTICORPS CONTRE CES PROTEINES
US6783961B1 (en) * 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
GB9810040D0 (en) * 1998-05-11 1998-07-08 Univ Nottingham Blood borne tumour markers
AU769756B2 (en) * 1998-11-03 2004-02-05 Mitokor Production of adenine nucleotide translocator (ANT), novel ANT ligands and screening assays therefor
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000050900A2 (en) 1999-02-26 2000-08-31 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
US6770445B1 (en) * 1999-02-26 2004-08-03 Pacific Northwest Research Institute Methods and compositions for diagnosing carcinomas
CA2296792A1 (en) 1999-02-26 2000-08-26 Genset S.A. Expressed sequence tags and encoded human proteins
US20030143234A1 (en) 1999-08-20 2003-07-31 Wenyuan Shi Anti-microbial targeting chimeric pharmaceutical
AU7067000A (en) * 1999-08-24 2001-03-19 Texas Biotechnology Corporation A polynucleotide encoding a human junctional adhesion protein (jam-2)
WO2001016354A1 (en) 1999-09-02 2001-03-08 Gene Logic, Inc. Modulation of he4 in inflammatory and renal diseases
WO2001018542A2 (en) * 1999-09-03 2001-03-15 Millennium Pharmaceuticals, Inc. Identification, assessment, prevention, and therapy of ovarian cancer
CA2397407A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
AU2001253140A1 (en) * 2000-04-03 2001-10-15 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Tumor markers in ovarian cancer
AU2001266787A1 (en) 2000-06-07 2002-01-08 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2002046765A2 (en) * 2000-11-08 2002-06-13 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of ovarian cancer
US20030087250A1 (en) 2001-03-14 2003-05-08 Millennium Pharmaceuticals, Inc. Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer
CA2448253A1 (en) * 2001-05-25 2002-11-28 Genset S.A. Human cdnas and proteins and uses thereof
US7270960B2 (en) 2001-08-29 2007-09-18 Pacific Northwest Research Institute Diagnosis of ovarian carcinomas
AU2003276852A1 (en) 2002-08-16 2004-03-03 Clinical Microarrays, Inc. Reading of fluorescent arrays
WO2004063355A2 (en) 2003-01-10 2004-07-29 Protein Design Labs, Inc. Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of matastatic cancer
JP4912894B2 (ja) * 2004-02-19 2012-04-11 イェール ユニバーシティー プロテオーム技術を使用した癌タンパク質バイオマーカーの同定
DE102004014645A1 (de) * 2004-03-25 2005-10-13 Mitsubishi Polyester Film Gmbh Transparente, elektrisch leitfähige, beschichtete Polyesterfolie, Verfahren zu ihrer Herstellung sowie ihre Verwendung
CA2578613A1 (en) * 2004-08-11 2007-01-25 Trubion Pharmaceuticals, Inc. Binding domain fusion proteins
ATE408828T1 (de) 2005-02-16 2008-10-15 Dana Farber Cancer Inst Inc Verfahren zur erkennung eines ovarialkarzinoms
WO2006135886A2 (en) 2005-06-13 2006-12-21 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CA2611173C (en) 2005-06-24 2019-11-12 Ciphergen Biosystems, Inc. Biomarkers for ovarian cancer
JP5164855B2 (ja) 2006-01-04 2013-03-21 フジレビオ アメリカ、インク． 子宮内膜または子宮癌を評価するためのｈｅ４及びそのほかの生化学的マーカーの使用
EP2087152B1 (en) * 2006-10-27 2015-03-11 Walfish, Paul Endometrial biomarkers
EP2121761A1 (en) * 2007-03-09 2009-11-25 Tripath Imaging, Inc. He4 monoclonal antibodies and methods for their use
BR112013004458A2 (pt) * 2010-08-26 2016-06-07 Univ Washington Ct Commerciali método e kit para detectar a presença de células que expressam he-4 em um indivíduo humano, e, método para o monitoramento de eficácia de tratamento de um paciente de câncer humano
CA2827618C (en) * 2011-02-17 2019-08-06 Fujirebio Diagnostics, Inc. Compositions and methods of use for the determination of he4a

Also Published As

Publication number Publication date
US20100047818A1 (en) 2010-02-25
CA2459077C (en) 2018-06-05
HK1214346A1 (en) 2016-07-22
CN1813188A (zh) 2006-08-02
US9090712B2 (en) 2015-07-28
EP1421388A2 (en) 2004-05-26
JP2016065870A (ja) 2016-04-28
US20160033512A1 (en) 2016-02-04
US7270960B2 (en) 2007-09-18
BR0212211A (pt) 2004-08-17
RU2004109149A (ru) 2005-05-10
JP2012161317A (ja) 2012-08-30
EP2322933A1 (en) 2011-05-18
US20090104684A1 (en) 2009-04-23
CA2459077A1 (en) 2003-03-13
JP2014081386A (ja) 2014-05-08
WO2003021273A3 (en) 2003-12-04
WO2003021273A2 (en) 2003-03-13
US20030108965A1 (en) 2003-06-12
EP2913673A1 (en) 2015-09-02
JP2009195240A (ja) 2009-09-03
JP5797136B2 (ja) 2015-10-21
JP2005501549A (ja) 2005-01-20
EP2913673B1 (en) 2017-05-31
KR20040062534A (ko) 2004-07-07
ES2628952T3 (es) 2017-08-04
JP5188443B2 (ja) 2013-04-24

Similar Documents

Publication Publication Date Title
MXPA04001963A (es) Diagnostico de carcinomas.
AU3007200A (en) Methods and compositions for diagnosing carcinomas
BRPI0820885B8 (pt) "anticorpo ou fraguimento do mesmo, célula de hibridoma, polinucleotídeo, polipeptídeo compreendendoum domínio de cadeia pesada ou leve de anticorpo, método para detecção de gravidez em um animal bovino, kit e método de purificação de um antígeno principal associado à gravidez (pag)".
WO2004070352A3 (en) Methods, mixtures, kits and compositions pertaining to analyte determination
CA2844033C (en) Method for detecting pancreatic cancer
WO2010021822A3 (en) Discovery of candidate biomarkers of in vivo apoptosis by global profiling of caspase cleavage sites
AR066224A1 (es) Articulo cementoso resistente al agua y metodo para prepararlo
EP1379693A4 (en) BIO STICK CODES BASED ON OLIGONUCLEOTIDE-MODIFIED PARTICLES
WO2006105152A3 (en) Amnion-derived cell compositions, methods of making and uses thereof
WO2004033631A8 (en) Nucleic acid and polypeptide sequences from lawsonia intracellularis and methods of using
WO2009019365A3 (fr) Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal
MXPA05006382A (es) Uso de nicotinamida n-metiltransferasa como un marcador para cancer colorrectal.
WO2008025964A3 (en) Antibodies to an epitope of agr2. assays and hybridomas
US20180284120A1 (en) Methods for determining a breast cancer-associated disease state and arrays for use in the methods
DE502005010086D1 (de) Monoklonaler antikörper gegen humanen frizzled-4-rezeptor
CN107367616B (zh) 一种前列腺特异性抗原检测试剂与试剂盒
WO2005077106A3 (en) Monoclonal antibody based biomarker discovery and development platform
NO20013563D0 (no) Fremgangsmåter og prövesett for sekvensering av polypeptider
AU8503898A (en) Monospecific antibody reactive with fibrinogen and fibrinopeptide
DE60328186D1 (de) Zusammensetzung für die herstellung von histologischen, autopsischen und zytologischen proben
US8257716B2 (en) Anti-PDEF antibodies and uses thereof
WO2009108949A3 (en) Cold shock protein compositions and methods and kits for the use thereof
ATE431556T1 (de) Bestimmung von kurzkettiger srl- alkoholdehydrogenase (dhrs4) als biomarker für entzündungen und infektionen
Dias STONECOLOR: Color of Commercial Marbles and Limestone: Causes and Changes
KR20160050727A (ko) 리포칼린 2 단백질에 특이적으로 결합하는 dna 앱타머 및 이의 용도